Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

NCT04374305 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

109

Enrollment

OTHER

Sponsor class

Conditions

Neurofibromatosis Type 2
Vestibular Schwannoma
Non-vestibular Schwannoma
Meningioma
Ependymoma

Interventions

DRUG: Brigatinib
DRUG: Neratinib
DRUG: Retifanlimab
DRUG: Bevacizumab

Sponsor

Scott R. Plotkin, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]